Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry

作者: Marta Nekulova , Jitka Holcakova , Rudolf Nenutil , Rembert Stratmann , Pavla Bouchalova

DOI: 10.1007/S00428-013-1459-4

关键词: Polyclonal antibodiesWestern blotAntibodyPhage displayBiologyMolecular biologyEpitope mappingEpitopeImmunohistochemistryMonoclonal antibodyPathology and Forensic MedicineCell biologyGeneral Medicine

摘要: The TP63 gene gives rise to protein isoforms with different properties and functions due the presence (TAp63) or absence (ΔNp63) of an N-terminal p53-like transactivation domain. Immunohistochemistry for p63 has clinical value certain tumour types, but investigations have been hampered by a lack well characterized antibodies inability discriminate between these opposite functional properties. We extensively series monoclonal recombinant human TAp63 two commercial monoclonals Western blot, immunostaining phage display epitope mapping. Twenty-eight 29 (96.6 %) novel that recognized all showed substantial cross-reactivity p73, as did antibody, 4A4. One clone, PANp63-6.1, slight cross-reaction p73 blotting not immunohistochemistry SFI-6 cross-react p53. Phage revealed PANp63-6.1 one amino acid difference 4A4 is identical in both, whereas unique p63, accounting findings. also produced TAp63-specific clone does recognize p53 we prepared polyclonal sera specific ΔNp63 isoforms. demonstrated expressed variety epithelial other cell types during development, often converse pattern ΔNp63, very limited expression normal adult tissues independent ΔNp63. was 17.6 % squamous cancers cervix unlike where expressed. associate proliferative index, cervical carcinomas improved survival. These data highlight need rigorous antibody characterization indicate p63-isoform identification may improve analyses.

参考文章(49)
M. Borba, C. Cernea, F. Dias, P. Faria, C. Bacchi, L. Brandão, A. Costa, Expression profile of p63 in 127 patients with laryngeal squamous cell carcinoma. Operations Research Letters. ,vol. 72, pp. 319- 324 ,(2010) , 10.1159/000319904
Marta Nekulova, Jitka Holcakova, Philip Coates, Borivoj Vojtesek, The role of P63 in cancer, stem cells and cancer stem cells Cellular & Molecular Biology Letters. ,vol. 16, pp. 296- 327 ,(2011) , 10.2478/S11658-011-0009-9
L Lo Muzio, A Santarelli, R Caltabiano, C Rubini, T Pieramici, N Giannone, F Carinci, R Leonardi, S Lanzafame, A Piattelli, p63 expression correlates with pathological features and biological behaviour of odontogenic tumours. Histopathology. ,vol. 49, pp. 211- 214 ,(2006) , 10.1111/J.1365-2559.2006.02423.X
Maximilian Moergel, Eva Abt, Marcus Stockinger, Martin Kunkel, Overexpression of p63 is associated with radiation resistance and prognosis in oral squamous cell carcinoma. Oral Oncology. ,vol. 46, pp. 667- 671 ,(2010) , 10.1016/J.ORALONCOLOGY.2010.06.012
Irina Matos, Rozany Dufloth, Marcelo Alvarenga, Luiz Carlos Zeferino, Fernando Schmitt, p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Archiv. ,vol. 447, pp. 688- 694 ,(2005) , 10.1007/S00428-005-0010-7
Xuecui Guo, William M. Keyes, Cristian Papazoglu, Johannes Zuber, Wangzhi Li, Scott W. Lowe, Hannes Vogel, Alea A. Mills, TAp63 induces senescence and suppresses tumorigenesis in vivo Nature Cell Biology. ,vol. 11, pp. 1451- 1457 ,(2009) , 10.1038/NCB1988
T Karn, L Hanker, E Ruckhaeberle, R Gaetje, C Solbach, M Schmidt, K Engels, U Holtrich, M Kaufmann, A Rody, None, Clinical relevance of the putative stem cell marker p63 in breast cancer Breast Cancer Research and Treatment. ,vol. 122, pp. 765- 775 ,(2010) , 10.1007/S10549-009-0608-6